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A 42-year-old man, who previously had been well, presented to
his family doctor feeling ill after a business trip to India, where he
had had an episode of diarrhea. There were no abnormal findings
on examination apart from a blood pressure of 180/110 mm Hg.
The urine had 3 + protein on dipstick testing, and a biochemical
screen and full blood count were performed. The plasma creati-
nine was 264 mol/liter (3 mg/dl); urea, 14 mmol/liter (90 mg/dl);
albumin, 4.3 g/dl; and calcium, 2.46 mmol/liter (9.8 mg/dl). The
hemoglobin was 10.9 g/dl; white blood cell count, 6.0 x lo9lliter;
and platelets, 221 X 109/liter. The patient was referred to our
Nephrology Unit for admission and evaluation. The only addi-
tional information obtained on admission was that he had taken
ibuprofen for backache six weeks previously.
The physical examination provided no new diagnostic clues.
The urine contained 20 X 106 red cells/liter and 100 X 10' white
blood cells/liter; there were no casts, and eosinophils were not
sought. A diagnosis of acute interstitial nephritis was entertained
and a renal biopsy performed, which was reported preliminarily as
consistent with this diagnosis. Oral prednisolone, 60 mg/day, was
instituted, but the serum creatinine rose to 880 jxmol/liter (10
mg/dl), and hemodialysis was begun. Two days later, three new
pieces of information became available: First, the results of an
employment medical examination nine months previously re-
vealed an ESR of 115 mm/hr. Second, the renal biopsy was
formally reported by the renal histopathologist as follows: "The
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cortical tissue contains 7 glomeruli. These glomeruli are showing
a little increase in mesangial matrix but no evidence of cellular
proliferation or neutrophil infiltration and the appearances give
no clue as to the cause of the acute renal failure. The main
abnormalities are in the interstitial and tubular tissues. Although
the majority of the tubules are within normal limits, there are
some containing casts and these have a fractured appearance.
There is one focus of interstitial lymphocytic and plasma cell
infiltration to be seen, but on the whole the biopsy is free from any
severe interstitial infiltrate. The morphology of the proximal
convoluted tubules which do not possess casts appears to be
within normal limits. Immunofluorescent preparation did not
reveal any deposition of immunoglobulins or complement within
the glomerular tufts. The possibility of myeloma should be
explored." Third, the urine contained Bence Jones protein, in
particular kappa chains. The serum had a band in the gamma
region, which proved to be an IgA kappa paraprotein at a
concentration of 46 g/Iiter. The IgG level was 3.7 g/liter and the
1gM level, 0.11 g/liter. The skeletal survey showed no lytic lesions.
A bone marrow aspirate disclosed 55% plasma cells. A diagnosis
of acute myeloma kidney was made.
The patient underwent five 4-liter plasma exchanges and started
on the first of his 5 cycles of treatment consisting of vincristine, 0.4
mg/day; doxorubicin, 9 mg/rn2; and oral dexamethasone, 40 mg/
day, on days 1 to 5 inclusive. His renal function transiently
improved to a creatinine clearance of 9 mi/mm, but a systemic
infection developed that was treated with gentamicin; he subse-
quently became dialysis dependent. Regular in-center hemodial-
ysis was begun, and he was later transferred to home hemodialysis.
Recombinant human erythropoietin treatment maintained his
hemoglobin at 12 g/dl without blood transfusion support.
The myelorna was controlled (paraprotein concentration of 6
glliter), but his course was complicated by two further episodes of
infection; first, an episode of staphylococcal septicemia related to
the Hickman line occurred nine months after presentation, and
second, an episode of bacterial pneumonia occurred 18 months
later. Severe breathlessness on effort prompted a cardiac exami-
nation 27 months after his presentation. His blood pressure was
120/80 mm Hg; jugular venous pressure was raised to 8 cm; and an
apical third heart sound and pulmonary congestion were present.
The electrocardiogram showed sinus rhythm with reduced voltage
and widespread lateral ST- and T-wave abnormalities. Cardiac
catheterization revealed generalized hypokinesis but no evidence
of occlusive coronary vascular disease. Five endomyocardial biop-
sies did not show the presence of amyloid, but there was extensive
fibrosis and a patchy cellular infiltrate. Hemodialysis became
difficult with episodes of hypotension and pulmonary edema
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between dialyses. He progressed to terminal heart failure, and he
died 30 months after his original presentation.
Discussion
DR. CHRISTOPHER G. WINEARLS (Consultant Nephrologist, Renal
Unit, The Churchill/John Radcliffe Hospital, Oxford, England): The
effects of myeloma on the kidney are diverse and usually sinister.
The presence of renal functional impairment has long been
recognized as a herald of a poor prognosis, as proved to be the
case in this patient. This patient with myeloma and acute renal
failure illustrates many facets of the entity, in particular, the speed
of onset and possible precipitants of acute renal failure, the risk of
irreversibility of renal failure, the value of renal biopsy, the
appropriate treatment, and the dangers of chemotherapy.
We can assume that this patient had myeloma some nine
months before he presented with renal failure, when his erythro-
cyte sedimentation rate was 115 mm/hr. In that silent interlude,
the burden of his disease increased until he developed acute renal
failure, which rapidly progressed to complete cessation of func-
tion requiring dialysis. Why this sudden catastrophe? First, the
concentration of light chains in the renal tubules might have
reached a critical and toxic concentration. Second, the diarrheal
illness leading to dehydration and the use of nonsteroidal anti-
inflammatory drugs might have contributed to the precipitation of
acute myeloma kidney, as demonstrated by the renal biopsy. It is
disappointing that his renal function did not recover, for he
received appropriate treatment of his myeloma. In the end,
neither the myeloma nor the renal failure caused his death. It is
possible that he developed a doxorubicin-induced cardiomyopa-
thy. My intent in this Forum is to provide an overview of acute
renal failure in myeloma and to shed light on how to improve
outcome in these patients.
Multiple myeloma, a diffuse neoplasm of bone marrow plasma
cells, exerts its effects locally as osteolytic bone lesions and
impaired hemopoiesis, and systemically by the action of the
abnormal immunoglobulin or light chain, culminating in renal
disease and susceptibility to infection. Approximately 40 new
cases per million population are diagnosed each year in England
and Wales, and a similar number of deaths are attributed to this
disease. It is a disease of older people; the median age at diagnosis
is 80 years in men and 70 years in women. Ten percent of deaths
occur in patients less than 50 years of age [1, 2].
Diagnostic criteria for myeloma include (1) a bone-marrow
aspirate containing >20% plasma cells or if <20% cells are of
monoclonal origin; (2) a serum monoclonal paraprotein; (3)
monoclonal light-chain excretion in the urine; and (4) lytic lesions
on radiologic inspection [3]. Two of these four features must be
present to establish the diagnosis. In approximately 54% of cases,
the abnormal immune globulin is an IgG; in 24% it is an IgA; in
less than 1% it is an IgD or IgE; and in 20% only light chains are
found [31.
Myeloma is not a curable condition for the majority of patients.
The aim of treatment is prolonging survival and maintaining the
patient's quality of life. However, diagnosis is often delayed. In
approximately 35% of patients, the interval between the onset of
symptoms and diagnosis is 3 months and in 15% it is >6 months
[1]. This delay is particularly relevant to the problem of myeloma
kidney, which sometimes can be prevented if treatment is insti-
tuted early, before catastrophic and irreversible injury has oc-
curred. The mainstay of treatment is chemotherapy with alkylat-
Table 1. Causes of renal involvement in myeloma
Acute reversible renal impairment
Dehydration
Hypercalcemia
Infection
"Myeloma kidney" (also called Bence Jones, myeloma, or light chain-
cast nephropathy)
Chronic renal failure
Irreversible cast nephropathy
Light-chain (AL) amyloid
Plasma cell infiltration
Proteinuria and the nephrotic syndrome
Light-chain deposition disease
Light-chain (AL) amyloid
Proximal tubular dysfunction (Fanconi syndrome)
ing agents such as melphalan and corticosteroids. Combination
chemotherapy regimens such as VAD [vincristine, adriamycin
(doxorubicin) and dexamethasone] or ABCM [doxorubicin,
BCNU (carmustine), cyclophosphamide, and melphalanl are gen-
erally used in younger patients but do not appear to offer a
significant advantage over treatment with melphalan. Allogeneic
and autologous bone marrow transplantation, which carry higher
risks, are offered to younger patients. It is appropriate to treat
patients who have renal failure energetically in the hope of
preventing its progression or reversing it.
Myeloma affects the kidney in a number of ways. The resulting
clinical presentations differ considerably (Table 1) [41. I will focus
in this Forum on acute renal failure [5—10]. Data from a cohort of
998 patients less than 75 years of age who fulfilled the Medical
Research Council (MRC) criteria for immediate chemotherapy
and who entered into trials of myeloma treatment between 1982
and 1991 show that 43% had abnormal renal function, defined as
a plasma creatinine >130 tmol/liter (1.5 mgldl) at presentation.
This classification was based on the level of plasma creatinine
measured after 48 hours of rehydration but before starting
chemotherapy. In the majority, plasma creatinine returned to the
normal range within three months, even if light-chain excretion
had not been reduced by therapy [1].
A clear difference exists between the majority of patients with
myeloma who present to hematologists and the minority managed
primarily by nephrologists. Rayner et al reviewed the local, and
therefore unselected, experience of 141 patients treated in Not-
tingham between 1975 and 1988 [11]. Of the 141 patients, 76 had
serum creatinines <120 mol/liter (rul.4 mg/dl) at diagnosis;
severe renal impairment [creatinine >500 iimol/liter (5.7 mgi
dl)] developed in only 7 (9%) of these patients. Only 4 of the 52
patients with modest renal impairment (creatinine >120 p.mol/
liter but <500 mol/liter) at diagnosis later developed severe
renal impairment. These data show that the absence of severe
renal impairment at presentation predicts a low probability of
developing renal failure subsequently. In all, 24 of 141 had severe
renal impairment at some stage; in 13 of 24 it was present at the
time of diagnosis. Eleven patients were dialyzed, and 4 recovered
sufficient renal function so that they did not need dialysis. The
relationship between renal impairment and survival is dramati-
cally illustrated by the median survival figures presented in this
same analysis [11]: median survival averaged 44, 18, and 4.3
months in patients with a plasma creatinine at diagnosis of < 120
mol/liter (1.4 mgldl, N = 70), 120 to 180 .tmolIliter (1.4 to 2.0
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mgldl, N = 27) and 180 j.tmol/liter (2.0 mg/dl, N = 42),
respectively. The data from the fifth MRC trial of treatment of
myeloma support this conclusion—only 50% of patients with
plasma creatinine concentrations >200 Mmol/liter (2.3 mgldl) at
presentation were alive at one year compared with nearly 80% of
those in whom it was <130 imol/liter (1.5 mg/dl) [7] (Fig. 1).
The different pattern of disease confronting nephrologists is well
illustrated by the 53 patients with myeloma and either acute or
chronic renal failure managed in the Oxford Renal Unit over the
last six years. In 64% of cases, renal failure was diagnosed within
one month of the diagnosis of myeloma, and in more than
one-half it antedated it; only 4 of the patients referred for
treatment of renal failure had had myeloma for more than six
months. This combination of nearly simultaneous diagnosis of
myeloma and renal failure is emphasized in other series [12—15].
There are two possible explanations for this combination—first,
that patients with established myeloma who subsequently develop
renal failure are not referred for dialysis. Our hematologists have
reassured us that this is not the case, although they do not refer
patients with progressive disease refractory to treatment whose
life expectancy is less than three months. The second possible
explanation is that treatment of the myeloma and control of the
tumor burden, paraprotein concentration, and presumably the
light-chain load in the tubules prevents the precipitation of
myeloma kidney. Although unproven, this is an attractive notion
and it underpins the reasoning behind aggressive treatment of
patients with both incipient and established renal failure.
Acute renal failure
I shall describe first our own series of 42 myeloma patients with
acute renal failure treated in Oxford over the last six years and
then draw on the published literature to explore some controver-
sial issues.
Clinical features. The Oxford Renal Unit serves a population of
2 million, providing both an acute renal failure service and renal
replacement for end-stage renal failure (ESRF). Patients with
myeloma represent a significant workload. Fifty-three patients
with myeloma were treated; of these, 42 had acute renal failure (7
cases per year). For reference, our service accepts 50 new patients
Light
IgG IgA
IgD or
IgE
chains
only
All myelomas [3] 54 24 <1 20
Myeloma and renal failure [28] 32 19 2 20
Myeloma and ARF [15] 31 7 — 62
Myeloma and ARF (Oxford) 34 19 10 37
with acute renal failure per year (excluding those admitted
directly to intensive care or developing acute renal failure in
intensive care) and accepts 60 patients per million for renal
replacement treatment for ESRF. There are no age barriers to
admission and dialysis treatment. The diagnosis of acute renal
failure relied on an acute presentation or a recent rapid rise in
plasma creatinine. Patients with other causes of renal failure such
as amyloidosis were excluded. The diagnosis of myeloma was
based on the criteria described earlier.
The mean plasma creatinine on admission was 896 481
imolI1iter (10 5.4 mgldl; range 302 to 2600 Mmol/liter, 3.4
to 29.5 mg/dl). This finding, and the fact that 22 of 42 required
immediate dialysis, shows that this cohort had severe renal
functional impairment. The average age was 66 10 years (range
42 to 82 years) and 2/3 of the patients were male. Although 24 of
42 were referred with a diagnosis of myeloma, the diagnosis had
been made less than one month previously in 18. In the remaining
18 patients, the diagnosis of myeloma was made by the nephrology
service. The myeloma was of advanced stage in the majority
(Stage 2b or 3b). The distribution of immunoglobulin classes is
given in Table 2. The striking difference in the distribution of
immunoglobulin classes between all patients with myeloma and
those with renal disease is the excess of pure light chain myeloma
in the latter group. IgD myeloma is believed to have the greatest
potential for causing renal disease [16]. The mean hemoglobin
was 9.5 1.9 gIdl; the mean marrow infiltrate was 48% (range 5%
to >90%); and lytic lesions were found in 26 of 38 on skeletal
survey. Twenty patients underwent renal biopsy; 14 of these had
classic "myeloma kidney" and 6 an acute interstitial nephritis
compatible with myeloma. No obvious precipitant of acute renal
failure could be identified in 29, but 8 had significant hypercalce-
mia and 4 had recently taken nonsteroidal anti-inflammatory
drugs; one was severely hypertensive (Table 3). The majority, 33
of 42, received chemotherapy. Sixteen patients thought to have
acute reversible injury were treated with plasma exchange, of
whom 6 showed an improvement in renal function sufficient in 3
to allow discontinuation of dialysis. Of the 26 patients not treated
with plasma exchange, one improved. Overall, 36 patients re-
quired dialysis and only 4 ever recovered sufficient function to be
independent of this treatment. Of the 31 deaths, 10 were caused
by progression of the disease, 4 by infection, and 4 followed
withdrawal of dialysis. Figures 2A and B show the actuarial
survival curves of the Oxford patients. Median survival for all
patients was 243 days; for those who survived at least 30 days, it
was 286 days. These poor survival figures can be explained by the
advanced stage of the myeloma given that most of the deaths were
a result of progressive disease.
Precipitants (Table 3). It is often difficult to indict a particular
event as precipitating renal failure because these patients suffer
a)>
100
80
60
40
20
0
Table 2. Distribution of immunoglobulin classes in myeloma (%)
<130
a Numbers in brackets refer to references.
0 1 2 3 4 5 6
Years in trial
Fig. 1. Survival figures in the 5th MRC myeloma trial. (Reprinted from
Ref. 7; © 1989 Munksgaard International Publishers Ltd., Copenhagen,
Denmark.)
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Table 3. Precipitants of acute renal failure in myeloma (in %)
Series
Number of
patients Dehydration Infection Hypercalemia
Contrast
medium NSAIDs None
Renal
recovery
Pozzi et a! [13] 50 24 8 34 4 0 44 50
Rota et a! [14] 34 65 44 44 0 26 — 47
Geneval et at [281 80 10 9 30 11 — 35 55
Oxford 42 — — 19 — 10 71 17
A
100
90
80
70
.2 60
> 50
40
30
20
10
0
B
100
90
80
— 70
60
5040
30
20
10
0
0 250 500 750
Time, days
1,000 1,250
0 250 500 750 1,000 1,250
Time, days
Fig. 2. Actuarial survival in the Oxford cohort of myeloma patients with
acute renal Jiilure. A. 42 patients: median survival of 243 days. B. 34
patients (who survived at least 30 days): median survival of 286 days.
many of the complications of the disease simultaneously. A
common thread seems to be an adverse effect on renal perfusion
caused, for example, by dehydration and/or infection (Table 3). It
seems clear that hypercalcemia, presumably by inducing dehydra-
tion, is an important precipitant (30% to 44%) but was evident in
only 19% of our patients. Calcium is thought by some to actually
increase the toxicity of the light chains [17].
We also know that a number of drugs are dangerous in patients
with myeloma. The most prominent offenders are the nonsteroi-
dal anti-inflammatory drugs (NSAID) often used to relieve bone
pain. Wu et al reported acute reversible renal failure in 2 patients
taking naproxen who were subsequently found to have myeloma
[18]. In neither case was another precipitant identified. Renal
function recovered in both, but renal histology was not reported;
hence, whether these patients had myeloma kidney, acute tubular
necrosis, or interstitial nephritis is uncertain. Responding to this
report, Shpilberg et at described a patient in whom convincing
evidence existed that naproxen precipitated acute myeloma kid-
ney [19]. Myeloma had been diagnosed five years before naproxen
was first used to treat an unexplained fever. Renal function had
been normal, but 10 days later the patient presented as an
emergency in uremia and died. At autopsy the classic features of
myeloma kidney were found and the casts stained positively for
lambda light chains by immunoperoxidase. Rota et al found that
6 of 8 of their oliguric patients had taken NSAIDs and that the
chance of recovery was diminished if these drugs were a precipi-
tating factor [14]. In our series, 4 of 42 patients gave a recent
history of having taken NSAIDs. The mechanism by which
NSAIDs cause a deterioration in renal function in patients with
myeloma is probably similar to that which operates in other
circumstances. Inhibition of cyclo-oxygenase reduces the produc-
tion of vasodilatory prostaglandins. This reduces GFR and, given
the natriuretic and diuretic effects of these prostaglandins, leads
to sodium and water retention. Cast precipitation is presumably
favored by the resulting increase in the tonicity of distal tubular
fluid [20].
Interferon alpha-2b sometimes is used as maintenance treat-
ment in patients with myeloma. Renal toxicity from this agent is
said to be rare, but cases of acute renal failure have been reported
with its use 1211. A stable patient developed acute renal failure 10
months after starting the drug. No other precipitant could be
identified, and a renal biopsy showed tubular damage without
casts, amyloid, or urate crystals. The renal failure resolved after
the interferon was stopped. A causal relationship has not been
proved in this case, but similarities with the case described by
Sawamura et al [22] increase suspicion. Precipitation of acute-on
chronic renal failure, irreversible in one case, also has been
described in patients receiving interferon alpha [23]. A transient
and reversible deterioration was observed in the only Oxford
patient treated with this agent. Intravenous immunoglobulin used
as prophylaxis against infection in so-called "plateau-phase"
myeloma is safe [65]. Concern had been raised because a rise in
plasma creatinine was observed in patients with the nephrotie
syndrome receiving high-dose IgG intravenously [241.
Radiographic contrast media have hitherto been considered an
important precipitant of acute renal failure [25].Contrast medium
was postulated to bind to intratubular proteins causing them to
precipitate and obstruct tubular fluid flow, McCarthy and Becker
reviewed 7 retrospective studies of myeloma patients receiving
contrast media [25]; 476 patients had undergone a total of 568
examinations. The incidence of acute renal failure (which was not
defined) was only 0.6% to 1.25% compared to 0.15% in the
general population. This relatively low risk contradicts the widely
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held opinion that contrast media are a sufficiently important cause
of acute renal failure in these patients to preclude their use. This
apparent change may reflect awareness of the risk and greater
care being taken to hydrate patients actively before and during the
administration of contrast media.
Pathology. Because renal biopsies are often performed when the
cause of renal failure is obscure, the first inkling of myeloma in a
patient is occasionally the finding of the classical histologic
appearance. The casts in acute myeloma kidney are found in the
distal convoluted tubule and collecting ducts [26]. Bright and
fissured, they are often surrounded by an inflammatory reaction
including giant cells. Immunostaining shows the presence of light
chain of the myeloma plasma cell type, albumin, Tamm-Horsfall
protein, and immunoglobulin. Electron microscopy shows that the
casts consist of crystals and fibrillar material.
The severity of tubular and interstitial damage is believed by
many to correlate with renal outcome but there is disagreement as
to whether the key indicator of outcome is the number of tubular
casts [13—15]. At best, the information obtained provides no more
than a rough guide. The question arises then: is a biopsy needed
if the diagnosis of myeloma has already been established? Argu-
ments in favor do exist. Other diagnoses such as acute tubular
necrosis, amyloidosis, light-chain deposition disease, or interstitial
nephritis may be revealed [27]. Treatment undoubtedly would be
modified in such cases, and plasma exchange would not be
advocated. If the interstitial lesions and the degree of fibrosis were
marked, implying that the injury was chronic, one might temper
how aggressive to be with chemotherapy. Renal biopsy is not
without risks, however, and the risks are greater in uremic
patients, who are often functionally thrombocytopenic.
Treatment. I believe that there are three critical elements of the
treatment of patients with acute myeloma kidney. First, we must
limit further cast precipitation. Measures to counter any precipi-
tating or aggravating factors are the priority. Such measures
include: rehydration, stopping NSAIDs, treatment of infections,
and reversing hypercalcemia. A forced alkaline diuresis aiming for
a urine flow of > 3 liters/day and a urine pH of —7 should be
attempted in all patients whose cardiac and renal function can
tolerate a deliberate expansion of the extracellular fluid volume
[7, 28]. These measures alone are sufficient to improve renal
function in the majority of patients with renal impairment at
presentation [7, 291.
Second, we should attempt to reduce the elevated paraprotein
concentration. Achieving this goal requires chemotherapy, usually
with an alkylating agent and high-dose corticosteroids. The choice
and efficacy of various regimens depends on the stage of the
disease and the general state of the patient [30]. The best
treatment for patients with renal failure cannot be established
from the literature. Many series describe patients treated over a
period when both chemotherapy and general management were
evolving. A combination of melphalan and prednisolone is the
standard first-line approach and will induce a remission in approx-
imately 40% of patients. This combination does not act rapidly,
and the dose of melphalan often has to be modified because the
drug is excreted via the kidney [31]. Using vincristine and doxo-
rubicin ("VAD" regimens) has advantages; these drugs act
quickly and are metabolized in the liver, making their use simpler
in patients with renal failure. Although a higher proportion of
patients achieve remission with this regimen than with melphalan
Table 4. Controlled trials of plasma exchange in multiple myeloma
Study Controlsa Plasma exchange"
Zucchelli et al [331 (n = 14) (n = 15)
Dialysis-dependent, recovered 11(2) 13 (11)
Oliguric 8 8
Improved or stable 5 13
Death < 2 months 5 1
—
Johnson et al [341 (n = 10) (n = 11)
Initial creatinine (j.unol/L) (SD) 730 300 880 540
Dialysis-dependent, recovered 5 (0) 7 (3)
Oliguric, recovered 1(0) 4 (3)
Long-term_dialysis 5 4
Peritoneal dialysis alone.
Hemodialysis and plasma exchange.
and prednisolone, neither survival nor duration of remission is
improved [30].
The application of plasmapheresis to reduce the concentration
of paraprotein rapidly has been advocated by many over the last
15 years, but its efficacy has not been established convincingly
[32—37]. In 1988 Zucchelli et al published the results of a
randomized comparison of hemodialysis and plasma exchange or
peritoneal dialysis alone in patients with severe acute renal failure
and myeloma [33]. All patients received chemotherapy. In the
hemodialysis and plasma exchange arm, 11 of 13 patients were
able to discontinue dialysis compared to only 2 of 14 in the control
group (peritoneal dialysis alone). However, interpretation is com-
plicated by the deaths of 5 patients in the control group in the first
two months (Table 4). The only other randomized prospective
trial examining this issue is that reported in 1990 by Johnson et al
[34]. Patients with renal failure (plasma creatinine >270 .tmol/
liter; 3.0 mg/dl) were treated with a forced diuresis and chemo-
therapy (melphalan and prednisolone). Twenty-one patients with
progressive renal impairment were then randomized to treatment
with 3 plasma exchanges per week for I to four weeks or no
plasma exchange. The results are summarized in Table 4. The
groups were similar except that 4 in the plasma exchange group
were oliguric. Overall, no difference was found in the number of
patients whose renal function improved. However, the authors
noted that the only patients with severe renal failure who improved
were those who had undergone plasma exchange. These authors
confirmed that plasma exchange produced a more rapid fall in
paraprotein concentration than did chemotherapy alone (Fig. 3).
A 4-liter plasma exchange can have only a small effect on the total
burden of light chains, given that these substances are distributed
throughout the extracellular fluid volume. Any effect must rely on
reducing the concentration below some critical, toxic threshold.
What is needed is a means for filtering much larger volumes of
extracellular fluid more rapidly.
Finally, I believe that dialysis should be started early in the
course of renal failure in patients with myeloma to avoid the
added complications of uremia and to compensate for the hyper-
catabolic state induced by the use of high doses of corticosteroids.
Recovery from renal failure is often delayed for many months
[38], so temporary vascular acccess for hemodialysis can pose
problems. The inevitable leukopenia that follows chemotherapy
increases the risk of line-related bacterial sepsis. To minimize this
complication, we advocate the early placement of a permanent
dialysis catheter.
1352 tJephro1ogy Forum: Acute myeloma kidney
a Data from Ref. 14.
bL = low, I = intermediate, H = high.
Table 5. Prognostic factors for recovery of renal function in patients
with myeloma and acute renal failure'
Recovery
n=16 No recoveryn=18 Pvalue
Gender 5F/11M 13F/5M <0.02
Age
Tumor mass
65
1L/3I/12H'
67
3L/21/12H
NS
NS
p1 6.5 6.5 NS
Calcium 2.8 2.6 NS
Infection 56% 33% NS
Oliguria 47% 50% NS
20 40 60 80 100
Days from start of chemotherapy Table 6. Reversal of renal failure and median survival of patients with
severe acute renal failure and myeloma (1985—1992)
Median
Series
Number of
patients % Reversal
survival
(months)
Cavo [53] 26 56 4
Rota [14] 34 47 19
Pozzi [13] 50 46 10
Misiani [37] 23 73 9
Pasquali [15] 37 43 9
Johnson [34] 21 57 22
Ganeval [28] 80 55 20
Mean (range) (271) 54 (43—73) 13 (4—22)
0
E
(1)
.i -20
. -40
ci)
2
o
-110
Fig. 3. Effect of plasma exchange on M-protein levels. S, chemotherapy and
plasmapheresis; 0, chemotherapy alone; p. number of plasmaphereses.
(From Ref. 34.)
Prognosis. Pozzi and colleagues, reporting for the Italian Renal
Imniunopathology Group, analyzed potential prognostic factors
in 50 patients with myeloma and acute renal failure (a rapid
increase in plasma creatinine to >2.5 mg/dl [>240 mmol/liter])
treated in 10 centers over 11 years [13]. Only 19 of the patients
were dialysis dependent, and in more than one-half they identified
reversible precipitants: hypercalcemia in 34% and dehydration in
24%. The cohort was therefore heterogeneous in terms of clinical
presentation and severity of renal failure. Four patients died early
and were excluded. Of the remaining 46, one-half showed an
improvement in renal function, and these were compared with
those who did not. The limitations of retrospective analysis of data
from multiple centers notwithstanding, some useful points
emerge. The group that improved had significantly lower plasma
creatinine concentrations at diagnosis and were less likely to be
oliguric. Patients with light-chain disease and numerous tubular
casts were less likely to recover. These findings suggest that the
combination of myeloma and renal functional impairment of any
degree should be treated as a medical emergency.
Rota et a! exhaustively analyzed clinical and pathologic features
in 34 patients with myeloma and acute renal failure in an attempt
to identify those factors predictive of complete or partial recovery
of renal function [14]. Myeloma was diagnosed according to
conventional criteria and staged according to the schema of Dune
and Salmon [39]. Acute renal failure was defined as a peak serum
creatinine of> 300 i.rmol/liter (3.4 mgldl). In 28 of 34 patients,
myeloma and renal failure were diagnosed simultaneously. Data
from these patients are remarkable; none of the factors that one
might guess would have predicted a higher chance for recovery of
renal function did so (Table 5). Age, tumor mass, peak creatinine,
oliguria, infection, and hypercalcemia all were similar in both
groups. The only difference was in the gender of the patients.—
fewer females recovered. Renal histology, which was available in
88% of patients, was highly informative. Renal function returned
to normal only in patients with typical cast nephropathy and/or
tubular necrosis in the absence of interstitial damage. The number
of tubular casts was not predictive. Global tubular atrophy and
interstitial fibrosis was associated with partial or totally irrevers-
ible renal failure. The isolectric point (p1) of the light chains was
similar in the two groups. This series differs markedly from ours in
that renal failure was partly or completely reversed in 47% of
cases. The authors emphasize that recovery from renal failure can
be delayed for many months. This observation is supported by
recent data from the Canadian Organ Replacement Register,
which found that 7.2% of myeloma patients established on dialysis
for >45 days recovered sufficient renal function to be independent
of dialysis for more than three months [38].
Table 6 lists the rates of recovery from acute renal failure in
myeloma in various series reported between 1986 and 1992.
Comparisons are difficult to interpret because the case mix was
different, particularly with reference to the severity and duration
of renal failure. In one [14] there was a high incidence of reversible
precipitants, and in another none were present and recovery was
infrequent [40].
The prognosis for survival largely depends on the stage of the
disease at the time of diagnosis and the response to treatment [28,
39]. What is the complicating effect of renal failure on survival?
Pasquali and colleagues performed a study in a single center of
the prognostic factors for survival in 37 patients with myeloma and
acute renal failure (creatinine > 5 mgldl, 440 .tmol/liter) [15];
follow-up data were available for these patients to death or to
survival for  36 months (Table 7). The authors confirmed the
association between light-chain myeloma and renal failure (Table
2) but did not find that the myeloma type or the p1 of the light
chain, disease stage, or patient age predicted prognosis. Hyper-
calcemia, early infections, and interstitial fibrosis detected on
renal biopsy were markers of a poor prognosis. They hinted that
plasma exchange treatment was associated with a greater chance
of recovery of renal function, itself a factor associated with longer
survival. The effect of recovering renal function on survival was
particularly striking in the series reported by Rota et al [14]. They
found that the median survival of those who experienced a
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Table 7. Prognostic features for survival in patients with acute renal
failure in myelomaa
Group 1 Group 2
(n=27) (n=10)
death in survival
< 12 months > 36 months P value
Females 33% 20% NS
Mean age 64 years 61 years NS
Stage III disease 81% 60% NS
Light-chain myeloma 59% 20% NS
p1 of light chain 6.8 1.1 6.6 1.3 NS
Hypercalcemia 33% 0% < 0.05
Early infection 44% 0% < 0.05
Dialysis 22/27 6/10 —
Oliguria 52% 20% NS
Renal recovery 30% 80% < 0.05
Plasma exchange 33% 70% < 0.05
Histologic features
Casts (2+ or 3+) 35% 11% NS
Interstitial fibrosis 57% 11% < 0.05
Tubular atrophy (2+ or 3+) 57% 11% < 0.05
a Adapted from Ref. 15.
Table 8. Relationship between tumor mass and renal functiona
Tumor mass
% Patients with serum creatinine
< 180/tmol/L 180—270/jirnol/L > 270/mol/L
Low
Intermediate
High
97
89
60
1
5
17
2
6
23
a Data from Ref. 29.
complete recovery was close to that of myeloma patients without
renal failure. A contrary conclusion was drawn by Alexanian et al,
who found that reversal of renal failure did not confer a survival
advantage [29]. This latter series included a number of patients
with transient, easily reversible renal impairment. In the series of
patients with severe renal failure described by Ganeval et al [28],
only response to chemotherapy, disease stage, and renal function
at one month were predictors of survival; age, gender, plasma cell
count, and the presence of skeletal deposits were not. Intuitively,
one might predict that the presence of renal failure, particularly
end-stage disease requiring dialysis, would adversely affect sur-
vival. The evidence, however, suggests that the complications of
renal replacement treatment per se are not a frequent cause of
death.
Pathogenesis. Is the presence of renal failure a sign of advanced
myeloma, or is it a sign of a particular form with a predilection for
damaging the kidney? I believe that both possibilities are true.
The evidence that the presence of renal failure is an indicator of
advanced disease comes from the data of Alexanian et al [29].
Table 8 shows the higher frequency of renal impairment in
patients with intermediate and large tumor mass. Moreover, the
risk of renal failure was 7%, 17%, and 39% in patients with daily
light-chain excretion of <0.005 g, 0.005 to 2.0 g, and >2.0 g,
respectively [291. However, patients with renal failure cannot be
regarded as having more aggressive disease because their re-
sponse to chemotherapy, periods of remission, and survival are
similar to those of patients with satisfactory renal function (Table
9).
Table 9. Prognosis of patients with high tumor massa
Serum creatinine bands (.tmols/L)
< 180 180—270 > 270 P value
n 96 26 36 —
Response rate 47% 36% 33% NS
Median remission 25 25 15 NS
(months)
Median survival 24 17 15 NS
(months)
a Data from Ref. 29.
A number of very persuasive pieces of evidence support the
belief that only particular forms of myeloma can cause severe
renal damage. First, although a large tumor mass is associated
with renal impairment, the majority of patients with advanced
disease have normal renal function [29]. Second, as noted, renal
failure is the initial finding in the majority of patients with
myeloma kidney [12—15].
Third, myeloma kidney occurs almost exclusively in patients
with Bence Jones proteinuria, and the risk for this complication of
the disease is highest in those with light-chain myeloma. No
convincing evidence exists, however, that the p1 of the light chain
is important as either a cause or a marker of renal damage [14, 41,
421. Fourth, the specific renal lesions of patients with myeloma
can be reproduced in mice injected with the purified abnormal
proteins [43]. That is, of 40 different human Bence Jones proteins,
26 were deposited in the mice, usually as tubular casts, basement
membrane precipitates, or crystals. In 18 cases it was possible to
compare renal tissue from the patients with that of mice injected
with their Bence Jones protein. Ten of the patients had cast
nephropathy, and in 8 of these, cast nephropathy also was found
in the mice. Material from 13 patients with plasma creatinines
<168 mo1es/liter (1.9 mgldl) served as controls. In only 4 of
these cases did the Bence Jones protein deposit in the murine
kidneys.
Although "nephrotoxic" light chains are necessary for the
development of cast nephropathy, their presence is frequently
insufficient to account for the development of the condition.
Renal failure can be reversed before the output of light chains has
been materially affected by chemotherapy and conversely can
develop without any increase in urinary concentration.
The understanding of the events occurring in the nephron
exposed to the nephrotoxic light chains has evolved from animal
experiments, in particular those by Sanders and colleagues, who
used an isolated tubule perfusion model [44—49] (Fig. 4A).
The kidney is itself responsible for the disposal of light chains,
which, when monomeric, are filtered freely, absorbed, and catab-
olized in the proximal tubular cells. The light chains bind to the
proximal tubule brush-border membranes via a single class of
low-affinity, high-capacity binding sites, which function as endo-
cytotic receptors [50]. The concentration of light chains in the
tubular fluid emanating from the proximal nephron depends
therefore on the plasma concentration and on the capacity of the
tubules to catabolize light chains. Dehydration or any renal injury
reducing GFR will increase the filtrate concentration, and any
proximal tubular injury will further increase the distal tubular
fluid concentration (Fig. 4A). Certain light chains are themselves
toxic to the proximal tubular cells (Fig. 4B) [44, 51]. Perfusion of
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Fig. 4A. The pathogenesis of myeloma kidney.
PCT, proximal convoluted tubule; DT, distal
tubule; PR, pars recta; CCT, cortical collecting
tubule; TAL, thin ascending limb; LC, light
chains; THP, Tamm-Horsfall protein.
Fig. 4Jt. Genesis of rnyeloma kidney.
the rat tubule with human Bence Jones protein causes a reduction of the cell. These effects are not produced by all purified Bence
in water and glucose reabsorption. The light chains can be Jones proteins [45]. The damage to the proximal tubule leads to
identified in the endosomes and activated lysosomes of these salt and water loss and dehydration, which starts a vicious circle of
tubular cells. Electron micrographs reveal cellular desquamation, falling GFR and reduced tubular clearance of light chains leading
cytoplasmic vacuolation, and focal loss of the microvillus border to a higher concentration in the tubular fluid presented to the
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distal tubule (Fig. 4B). Light chains co-precipitate with Tamm-
Horsfall protein in the thin ascending limb of the ioop of Henle to
form the casts that obstruct tubular fluid flow leading to disrup-
tion of the basement membrane and to leakage into the intersti-
tium.
The light chains that have the capacity to obstruct tubules in the
perfusion model are the ones that co-precipitate with Tamm-
Horsfall protein in vitro [461. So it seems that cast formation is
dependent on the properties of the light chain [48], particularly on
their ability to bind to a particular peptide part of the Tamm-
Horsfall molecule [49J. Obstruction of the tubule depends on the
concentration of the light chain and is aggravated by loop
diuretics. Co-precipitation with Tamm-Horsfall protein can be
prevented by pre-treating animals with colchicine, which not only
diminishes excretion of the protein, but changes its carbohydrate
content [47]. Recently Myatt et al, using size-exclusion chroma-
tography, showed that light chains with a capacity to cause renal
damage in vivo undergo self-association to form high-molecular-
weight aggregates under physiologic conditions [521. This obser-
vation suggests a further mechanism for the precipitation of
certain light chains as casts in the distal tubule.
Concluding remarks
The combination of myeloma and acute renal failure is a
sufficiently common presentation that it should always enter the
differential diagnosis of unexplained acute renal failure. Patients
presenting with this combination are a medical emergency, requir-
ing a limited number of highly informative investigations and a
clear plan of management. A thorough knowledge of the natural
history and prognosis is prerequisite for counseling the patient.
The first order of business is the renal failure, which should be
assumed to be reversible. The institution of chemotherapy, the
effect of which will not be immediate, comes second. The initial
aims are to restore or maintain urine flow and to identify and
counter any aggravating factor or precipitating cause of the
reduced renal function. A diuresis should be established, hyper-
calcemia should be treated with diphosphonates if not reversed by
rehydration, nonsteroidal anti-inflammatory drugs should be es-
chewed, and infections should be treated with non-nephrotoxic
antibiotics.
After the renal failure is dealt with, attention can be turned to
the myeloma. Typically, the choice will be between a combination
of melphalan and prednisolone, on the one hand, and VAD
(vincristine, doxorubicin, and dexamethasone) or ABCM (doxo-
rubicin, carmustine, cyclophosphamide, and melphalan), on the
other. The latter, more toxic regimens should be reserved for
patients with aggressive and advanced tumors whose age and
general state do not preclude their use. As yet, no firm recom-
mendation on the utility of plasma exchange can be made, but
sufficient suggestive evidence justifies its use in patients with
rapidly rising plasma creatinine values and high concentrations of
paraprotein.
Renal biopsy is not mandatory, but it can be useful if causes of
renal failure other than myeloma kidney are a consideration. The
limited prognostic information provided by a renal biopsy is,
however, not sufficient by itself to justify the risk of the procedure.
Virtually inevitably, the patient will die of myeloma at some
point, but survival with a reasonable quality of life on dialysis is
the rule. I believe that there is little difference between CAPD and
hemodialysis. At best, survival of patients with renal failure is no
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Fig. 5. Survival of myeloma patients with renal cell cancer (U), multiple
myeloma (A), and amyloidosis (0). Data from the USA ESRD Networks,
1983—1985. (Reprinted from Ref. 54 by permission of Oxford University
Press.)
worse than that for patients without renal failure whose myeloma
is at a similar stage [8]. Dialysis should be instituted early to avoid
uremia compounding the complications of the underlying disease.
About 20% of patients will die within the first month, but it is not
possible to predict who these will be. Because 50% of the
survivors will live for more than one year, and because recovery of
renal function is often delayed for several months, a policy of
offering dialysis to all patients is justified. Port and Nissenson
reported the outcome in 731 patients with myeloma who started
ESRD therapy in the USA from 1983 to 1985 [54]. Although the
proportion of these patients who presented with acute myeloma
kidney was not given, the data from this uniquely large cohort are
very useful. Seventy-five percent of the patients in this series were
more than 60 years old. The one-year survival was 54%. By 20
months, the survival rate was down to 25% compared with 66%
for other nondiabetic ESRD patients (Fig. 5). The prognosis thus
is poor but not hopeless, and dialysis represents an acceptable
form of adjunctive palliative care, provided the quality of life is
reasonable.
Can acute renal failure in patients with myeloma be prevented?
Given that the majority of patients with renal disease present late,
when the insoluble casts have already wreaked havoc in the
tubules, prevention is unlikely. However, our understanding of the
toxic injury to the proximal tubule and the processes leading to
cast formation in the loop of Henle may provide strategies for
halting the disease as soon as it is recognized.
Questions and answers
DR. JoHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): Are there
data showing that one can experimentally block the light-chain
receptor in the proximal tubule and simultaneously prevent renal
dysfunction?
DR. WINEARLS: No. There is competition for the binding site by
both kappa and lambda light chains, so theoretically one could
block the uptake of a pathogenetic Bence Jones protein with a
non-pathogenetic one [50]. This would not prevent the critical
lesion in the distal tubule.
DR. ALEX M. DAVISON (Consultant Renal Physician, St. James's
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University Hospital, Leeds, U.K): May I follow Dr. Harrington's
question by suggesting that blocking proximal tubular reabsorp-
tion of light chains might allow for more light chains to reach the
thick ascending limb of the loop of Henle, where, in the presence
of Tamm-Horsfall glycoprotein, precipitation may occur with
subsequent damage. It might be that the degree of overall
proteinuria is saturating the proximal tubular protein reabsorp-
tion system, thereby allowing for more light chains to reach the
distal tubule with consequent damage. Do you know whether any
relationship exists between total protein excretion and the risk of
renal failure?
DR. WINEARLS: I have not found any study of the quantification
of non-light-chain proteinuria in myeloma or its effect on the risk
of the development of myeloma kidney.
DR. DAVISON: I'd like to follow up on that. We have been
looking at the glomerular charge in the basement membrane. In
paraproteinemias and in myeloma renal disease, we can detect
very significant changes in charge unlike those in most other forms
of glomerular disease.
DR. GREGORY G. VOSNIDES (Chief Division of Nephrology,
Laiko General Hospita4 Athens, Greece): Apart from the intersti-
tial fibrosis, would you consider the presence of amyloidosis in
renal biopsy to be of prognostic value? The reason I ask is because
it is our impression in a limited number of patients that the
coexistence of amyloidosis with cast nephropathy is probably of
some predictive value.
DR. WmnARIs: I have not seen both lesions in the same kidney,
but Ganeval reported 2 patients who had presented with myeloma
kidney who subsequently developed amyloidosis [28].
DR. V0SNIDEs: Do you have any data on the value of immuno-
absorption, instead of plasma exchange, in the therapeutic man-
agement of acute myeloma kidney?
DR. WINEARLS: I have no experience with that, nor am I sure
whether the Protein A columns would absorb isolated light chains.
PROF. FRANCESCO PAOLO SCHENA (Chairman, Institute of Ne-
phrology, University of Ban, Bari, Italy): My question relates to the
type of chemotherapy. You referred to chemotherapy, using
melphalan and corticosteroids, or the VAD and ABCM combi-
nation schemes, and plasma exchange. We have had good reso-
lution of acute renal failure in patients with myeloma kidney and
acute renal insufficiency by administering intravenous pulse ther-
apy with methylprednisolone for 3 consecutive days and giving
cyclophosphamide orally. Do you have any experience with that
chemotherapeutic regimen or information from the literature?
DR. WINEARLS: I have no experience of the regimen you
describe. My review of the literature did not reveal any evidence
for the particular efficacy of any combination of drugs in reversing
acute renal failure. Moreover, MacLennan et al emphasize that
much of the improvement in renal function occurs before any
change in light-chain production could be effected [7].
DR. MICHEL OLMER (Chief of Nephrology-Dialysis Unit, Hôpital
de Ia Conception, Marseille, France): Because of the poor median
survival you reported, I would like to report our own experience.
We have been using oral prednisolone continuously, 10 mg/day,
following 3 or four days of 60 mg methylprednisolone adminis-
tered intravenously. In addition, we administer cyclophospha-
mide, 0,75 mg or 1.0 g/day every 10 to 15 days for six months, and
then 0.8 to 1.0 g intravenously each month for as long as the
patient survives. Our median survival rate appears to exceed one
year, and for some patients more than two years, without evidence
of toxic anemia.
DR. WINEARLS: The implication of this statement is that survival
depends on the choice of chemotherapy. The benefits of one
regimen over another seem to be marginal, inconsistent, and
arguable [1—3, 28, 30]. Comparisons of small series of patients are
not valid, for one cannot assume that patient selection, disease
stage, or the incidence of co-morbid factors were similar. In our
series, 9 of 42 patients did not receive any chemotherapy because
their clinical state was such that it was not deemed appropriate.
There is, moreover, no evidence that continuous chemotherapy
after a response has been achieved confers a survival advantage
(reviewed in Ref. 30).
PROF. PIERRE RoNco (Professor of Nephnology, Pierre et Mane
Curie University, Paris, France): I have two comments regarding
the composition of proteinuria and counting casts in renal biop-
sies of patients with myeloma cast nephropathy. We have looked
at the composition of proteinuria in a series of 34 myeloma
patients, including 30 with biopsy-proven cast nephropathy [141.
Urinary light chains accounted for 70% or more of total protein-
uria in 80% of the patients. The remaining proteins are composed
of albumin and low-molecular-weight globulins that have failed to
be reabsorbed by proximal tubule cells. In the rare patients with
albuminuria over 1 g/day, cast nephropathy is usually associated
with glomerular lesions due to amyloidosis or monoclonal immu-
noglobulin deposition disease.
Counting casts in renal biopsy specimens taken from the
superficial cortex may be inappropriate because most casts are
located in the lumina of distal tubules and collecting ducts, that is,
in deep cortex and medulla. It is, however, possible to estimate the
percentage of cast-obstructed nephons by searching for the pres-
ence of Tamm-Horsfall protein (THP) in glomerular urinary
spaces, a marker of urinary back-flow [55]. Fifty-five of the 119
glomeruli available for study (46%) in 16 of 18 biopsies from
patients with cast nephropathy stained for THP [56]. It is worth
noting that THP also was found in glomeruli of a myeloma patient
with severe tubular lesions, but without casts visible on a super-
ficial renal biopsy.
DR. WINEARLS: Presumably the Tamm-Horsfall protein is re-
fluxing back up the tubule, but it does not mean that it is causing
injury in the proximal tubule.
DR. RoNco: There is no evidence that THP causes renal
damage when located within proximal tubule lumina or glomer-
ular urinary spaces.
DR. FERNANDO VALDERRABANO (Chairman, Department of Ne-
phrology, Hospital General Universitario Gregorio Marañon, Mad-
rid, Spain): The precipitant of acute renal failure in the case
presented seems to be dehydration. In fact, the patient had had
diarrhea, but surprisingly he was hypertensive. Can you make any
comments on this fact and on the presence of hypertension in
myeloma kidney in general?
DR. WINEARLS: I am not sure what the crucial precipitant of
renal failure in this patient was. The episode of diarrhea and the
consumption of a nonsteroidal anti-inflammatory drug were rel-
atively remote from the time of his presentation when he was not
dehydrated and had a raised blood pressure. The progression of
his renal failure was very rapid. I attribute this to catastrophic cast
formation after the concentration of light chains exceeded a
critical point. In the series I have reviewed, severe hypertension
was rare and was seldom indicted as the cause of renal failure. It
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is presumably a reflection of the fluid overload caused by renal
failure.
DR. ERLINO B. PEDERSEN (ChiefPhysician, Department of Med-
icine and Nephrology C, University Hospital, Aarhus, Denmark):
Are nonsteroidal anti-inflammatory drugs contraindicated in mul-
tiple myeloma? My other question relates to pulse compared to
continuous cytostatic treatment. What do you think is the best
treatment?
DR. WJNEARLS: Nonsteroidal anti-inflammatory drugs have
little effect on glomerular filtration or on tubular handling of
sodium in subjects with normal renal function. The effects are
usually seen in patients who have pre-existing problems such as
cirrhosis of the liver, congestive heart failure, or renal impair-
ment. I think they are absolutely contraindicated in myeloma
patients with any degree of renal impairment. I believe these
patients are often on the brink of acute myeloma kidney, and
nonsteroidal anti-inflammatory drugs may be sufficient to tip the
balance. The mechanism may be no more complicated than a
reduction in GFR because of the inhibition of the production of
vasodilatory prostaglandins, but it may be the effect of rionsteroi-
dal anti-inflammatory drugs on sodium and water handling on the
distal tubule raising the concentration of the light chains there to
a point favoring cast formation. Continuous treatment has not
been shown to prolong survival, but it may delay relapse (reviewed
in Ref. 30).
DR. YVES PIR50N (Associate Professor, University of Louvain
Medical School, Brussels, Belgium): What is the actual rate of
toxicity from contrast media in patients with myeloma? It seems to
me that the likelihood of toxicity has been overemphasized in the
past. What is your recommendation in a patient with myeloma
who requires examination with contrast media? Should we use
non-ionic contrast media, or does it matter?
DR. WINEARLS: The risk of contrast media inducing renal failure
does seem to have been exaggerated, and one wonders whether it
was the dehydration required for preparation that was more
important. The estimated risk of acute renal failure, although the
severity was not specified, was 0.6% to 1.25% [25]. My recom-
mendation is that if the clinical need arises, the investigation
should be performed after adequate hydration of the patient. I am
not aware of any data comparing the risks of ionic and non-ionic
contrast media.
DR. JORDAN J. COHEN (President, Association of American
Medical Colleges, Washington, D.C.): What damages the proximal
tubule epithelium in acute myeloma kidney? Is it the light chains
per se or the overload of the proximal tubule cell consequent to
excessive light-chain reabsorption? Does the biochemical nature
of the light chain make a difference, for example, p1, kappa versus
lambda?
DR. W!NEARLS: The data from Sanders' experiments suggest
that particular light chains are toxic to the proximal tubules and
others are not. In vivo, proximal tubule perfusion with a particular
Bence Jones protein altered volume, chloride, and glucose fluxes
and caused cell damage including atypical lysosomes containing
crystals. Perfusion with two other Bence Jones proteins induced
neither functional changes nor morphologic changes despite
evidence of endocytosis of the proteins. Neither isoelectric point
nor isotype were factors associated with proximal tubule damage
[45]. There has been much controversy over whether the isoelec-
tric point of the light chain is relevant to nephrotoxicity [reviewed
in Ref. 57]. The overall conclusion is that it is not. However, light
chains with a p1 in the basic range produce more proximal tubular
dysfunction than do acidic light chains [42].
DR. KARL M. KOCH (Professor of Medicine, Med izinische Hoch-
schule, Hannover, Germany): I would like to come back to the
controversial issue of plasma exchange. My understanding is that
you apply it in all your cases. Don't you think it is advisable to
restrict the application of plasma exchange to oliguric patients
who have high plasma levels of light chains? Only in that situation
will you remove significant amounts of light chains.
DR. WINEARLS: Our use of plasma exchange was inconsistent
and depended on a clinical judgment as to whether the onset of
renal failure had been acute and therefore potentially reversible.
Given the distribution of light chains in the extracellular fluid
volume, plasma exchange is a relatively inefficient means of
removing them. The need exists for another randomized trial in
patients who have proven cast nephropathy on renal biopsy and
whose renal function deteriorates despite the application of
conventional measures.
DR. DONTSCHO KERJASCHU (Professor of Pathology, Department
of Clinical Pathology, University of Vienna, Vienna, Austria): What
is known about the nature of interaction of light chains and
Tamm-Horsfall protein? Is there a protein-protein or protein-
carbohydrate interaction?
DR. WINEARLS: Sanders and Booker have shown that cast-
forming human Bence Jones proteins (BJPs) co-aggregate with
Tamm-Horsfall glycoprotein (THG). However, the THG ob-
tained from colchicine-treated rats did not contain sialic acid and
did not aggregate with the Bence Jones protein in vitro [47, 48].
They have gone on to show that different BJPs bind THG with
different affinities. The binding site on THG is apparently a
peptide because the BJPs are able to bind to deglycosylated THG.
Co-aggregation of THG and BJP did depend on the carbohydrate
moiety of the THG [49].
DR. MICHEL LESKI (Head, Division of Nephrology, Hôpital
Cantonal Universitaire, Geneva, Switzerland): Please comment on
the relationship between the questionable efficacy of plasma
exchange and the rather short half-life of light chains. How does
the latter influence therapeutic strategy?
DR. WINEARLS: I agree that plasma exchange is an inefficient
way of removing light chains.
DR. LANDINO ALLEGRI (Institute of Medicine and Nephrology,
University of Parma, Parma, Italy): Some factors, such as hyper-
calcemia, have been shown to increase, at least at the experimen-
tal level, the toxicity of Bence Jones proteins. Is there any
evidence that tumor-derived factors, such as lymphokines, com-
bine with particular light chains to increase the resultant renal
injury?
DR. WINEARLS: The suggestion that hypercalcemia increases the
toxicity of light chains comes from experiments reported by
Smolens et a! [17]. Infusion of a Bence Jones protein into rats
made hypercalcemic caused a decrease in GFR not observed in
animals made hypercalemic or infused with the protein alone.
This change was not associated with an increase in cast formation.
I am not aware of any evidence of lymphokines exacerbating renal
injury in myeloma patients.
DR. L. A. VAN Es (Department of Nephrology, Leiden University,
Leiden, The Netherlands): Light chains differ in degree of dimer-
ization and consequently in their sieving coefficient. Have you
observed a correlation between the size of excreted light chains or
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the filtered load, on the one hand, and the severity of renal injury,
on the other?
DR. WINEARLS: We did not measure the size of the light chains.
The data from Alexanian et al do show a direct relationship
between the filtered load of Bence Jones protein and the risk of
renal failure [29].
DR. TuLuo BERTAN! (Division of Nephrology, Mario Negri
Institute, Bergamo, Italy): In 1980, when I was in the laboratory of
Dr. Pirani in New York, I injected mice with large amounts of
different light chains, but I was unable to reproduce a cast
nephropathy even in the presence of hypercalcemia and dehydra-
tion. This indicates that not all light chains are able to induce cast
nephropathy and that probably a specific "toxic" effect of light
chains on proximal tubule cells is required to induce renal
damage.
DR. WINEARLS: Some light chains cause the Fanconi syndrome
and not myeloma kidney, implying an effect only on the proximal
tubule. I am suggesting that the combination of proximal tubular
injury, which increases the load of light chains distally, and the
propensity to form casts sets up the conditions that lead to
myeloma kidney. Proximal tubular injury need not be present for
renal failure to occur if the load of light chains reaching the distal
tubule is sufficient to precipitate as casts.
DR. LORETO GESUALDO (Institute of Nephrology, University of
Bari): I'd like to return to Dr. Cohen's question. If your pathoge-
netic hypothesis is correct that the proximal tubule cells are the
first to be damaged, do you think that we can measure substances
in the urine that can predict acute renal failure?
DR. WIA1s: Evidence of tubular injury can be inferred from
the finding of increased urinary output of the tubular lysozymal
enzyme N-acetyl-beta-D-glucosaminodase [58].
DR. TILMAN DRUEKE (Director, Unite 90 de L 'INSERM, and
Associate Professor, Division of Nephrology, Hôpital Necker, Paris,
France): Much interest has focused on the direct toxic effects of
myeloma light chains on the tubular epithelium. However, the
degree of severity and the prognosis of acute renal failure in
mycloma depends mainly on the extension of interstitial fibrosis.
Is it possible that some type of light chains are particularly toxic
for the interstitium, and that such light chains even move directly
from the renal vessels to the interstitium, thereby activating
fibroblast activity and stimulating collagen production?
DR. WINEARLS: I suppose that is possible, but leakage into the
interstitium following disruption of the obstructed tubule seems
more likely.
DR. KOSTAS C. SIAMOPOULOS (Associate Professor of Medicine!
Nephrology, University Hospital of loannina, loannina, Greece): In
contrast to our knowledge about multiple myeloma as a systemic
disease, what do we know about the association of plasmacytomas
and renal lesions?
DR. WTNEARLS: I didn't find any distinction made between
isolated plasmacytomas and multiple myeloma.
DR. S1oPouLos: What if the plasmacytoma is non-secretory?
DR. WINEARLS: Although free light chains in the urine seem to
be a prerequisite for myeloma kidney, not every patient has free
light chains. The exception is in IgD myeloma. A substantial
minority of these patients with myeloma kidney do not have
detectable light chains in the urine—perhaps because the light
chains are present in a very low concentration [16].
DR. GIUSEPPE REMUZZI (Director, Mario Negri Institute): I have
a comment on pathogenesis. Proximal tubular toxicity of light
chains could be regarded as an extreme example of a phenome-
non common to a number of different proteinuric conditions, all
of which tend to progress to renal failure, with biopsy findings of
interstitial inflammation and fibrosis. I would like to stress that
tubulointerstitial damage is a crucial factor associated with poor
long-term prognosis in most proteinuric renal diseases.
DR. WINEARLS: Presumably the extent of interstitial fibrosis
depends on the duration of the injury. Patients presenting with
acute oliguric renal failure have no or little interstitial fibrosis but
prominent distal casts.
DR. REMuzzI: These probably are patients with distal tubule
obstruction like the ones who stop making urine immediately after
infusion of large amounts of dextran-40 after cardiac surgery. On
a completely different subject, the two trials you presented on
plasma exchange produced apparently contradictory results. I
would like, however, to raise the issue of adequacy of sample size
for these kinds of studies that might not have the power to detect
differences even if they exist. Given the cost and the risks
associated with plasma exchange in these patients, I believe that it
is time to start a multicenter effort to settle this important issue.
DR. WINEARLS: I agree. Sufficient data exist to suggest that, on
balance, plasma exchange is beneficial. This is not a trivial
procedure; it is expensive and it has risks. The potential benefit of
reversing renal failure would justify such a trial.
DR. RoNco: In a recent study devoted to physicochemical
properties of light chains in myeloma-associated tubulopathies,
including 4 patients with Fanconi syndrome and 12 with cast
nephropathy, we found that Fanconi syndrome was characterized
by the generation in the presence of cathepsin B, a lysosomal
enzyme, of a 12-kDa fragment corresponding to the variable
domain of the kappa chain [59]. This fragment, which was
resistant to further proteolytic attack, was the predominant com-
ponent of crystals forming spontaneously from the patient's urine
[60]. The peculiar proneness of the variable domain to resist
proteolysis might explain its accumulation in phagolysosomes of
proximal tubular cells. On the other hand, light chains from
patients with cast nephropathy were distinguished from those
obtained from controls by their frequent reactivity with THP
(7/12); as a rule, the entire molecule or a fragment thereof was
resistant to proteolysis, whereas none showed prolonged resis-
tance to cathepsin B. Cast nephropathy is a heterogeneous entity,
the pathogenesis of which might involve multiple factors such as
protease resistance in addition to light-chain reactivity with THP.
DR. CHARLES VAN YPERSELE (Chief Renal Unit, and Professor of
Medicine, University of Louvain Medical School, Brussels, Belgium):
You observed a poor outcome in your large series of patients.
Have you drawn any lessons from this experience that might give
us a clue as to what should not be done? In particular, is it
conceivable that the systematic use of plasmapheresis has contrib-
uted to this poor outcome?
DR. WINEARLS: Plasmapheresis was not a cause of the high
mortality. I think that the relatively high mortality in our series
reflects the age of patients, stage of disease, and the severity of
their renal injury.
DR. JOHN DONOHOE (Department of Nephrology, Beaumont
Hospital, Dublin, Ireland): From the EDTA Registry, we know
that just as in lupus nephritis, malignant hypertension, or sciero-
derma kidney, some patients with myeloma on long-term dialysis
regain sufficient renal function to become dialysis independent.
Are there any factors that can be identified in this group of
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patients that can provide clues to a more favorable prognosis?
May I also ask you to comment on studies in which repeat renal
biopsies have been performed?
DR. WINEARLS: The likelihood of recovery has been looked at in
the Canadian Organ Replacement Register [381. Multiple my-
eloma is the commonest disease in which recovery from dialysis-
dependent renal failure (dialysis >45 days) is seen, but this
recovery is usually delayed and incomplete. I could not find any
constant factors that point to a greater chance of recovery of renal
failure.
There are no series in which systematic followup biopsies have
been performed. Ganeval et a! described repeat biopsies in 3 of 30
of their patients with biopsy-proven myeloma kidney. One patient
had developed light-chain deposition disease, and two had amy-
loidosis. Hill and colleagues obtained 6 repeat specimens from 43
patients with renal complications of myeloma [61]. Myeloma casts
were markedly diminished in all 6, but in 3 cases were replaced by
massive tissue deposits of light chains (kappa in two, amyloid in
one). The reduction in casts did not necessarily equate with
improvement, for 3 remained on dialysis and one had serious
chronic renal failure.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): You referred to
the plasma creatinine level at presentation (following hydration
but before initiation of chemotherapy) as a prognosticator of
eventual renal outcome. Was the level of plasma creatinine
assessed after substantial hypercalcemia also was controlled?
After all, hypercalcemia can lead to functional azotemia on the
basis of renal vasoconstriction. In fact, similar to the sodium-
retentive states you mentioned, hypercalcemia is another condi-
tion that renders the kidney sensitive to the nephrotoxic effects of
nonsteroidal anti-inflammatory drugs.
DR. WINEARLS: The studies to which I referred were the MRC's
4th and 5th Myelomatosis Trials [7]. Control of hypercalcemia was
not specifically mentioned in their subdivision of degrees of renal
failure. Hypercalcemia is, of course, a marker of advanced
disease, but its presence has not been shown to be a prognostic
factor for recovery [141 as it is for survival [15].
DR. JOSEPH B. ROSENFELD (Department of Nephrology, Beilinson
Medical Center, Tel-Aviv University Medical Schoo4 Tel-Aviv, Isra-
el): Considering the increased viscosity of the plasma in patients
with myeloma, have there been any studies relating the disturbed
renal circulation and hypoxia to the observed renal lesions?
DR. WINEARLS: Not that I am aware of.
DR. PHILIPPE LESAVRE (Department of Nephrology, Hôpital
Necker): Tamm-Horsfall protein and light chains are the two
major partners in the formation of casts in myeloma kidney. Do
you think that there is place for a third partner protein that either
increases precipitability or delivers pro-inflammatory signals?
Besides Tamm-Horsfall protein and light chains, does the direct
analysis of protein composition of the casts identify other pro-
teins? For example, is complement protein C9 present? I ask
because this protein can increase aggregability even if present in
minute amounts.
DR. WINEARLS: The casts certainly excite an intense inflamma-
tory reaction. Immunofluorescence shows that the cast can con-
tain (in addition to light chain and Tamm-Horsfall protein)
albumin, other immuloglobulins, and complement. I do not know
whether C9 has been found in casts [26, 62].
DR. PANOS ZIROYANIS (Chief Division of Nephrology, General
State Hospital, Athens, Greece): Do you know of any data compar-
ing the outcome of patients with acute myeloma kidney treated
with hemodialysis versus those treated with peritoneal dialysis?
DR. WINEARLS: Peritoneal dialysis is thought by some to be
preferable to hemodialysis, as it is more effective in removing light
chains [63]. However, the trial reported by Zucchelli et al showed
that patients treated by hemodialysis and plasma exchange were
more likely to recover renal function than were those treated by
peritoneal dialysis alone [33].
DR. ALLEGRI: According to your experience, are there selected
cases in which renal transplantation is indicated?
DR. WINEARLS: Patients with myelorna have received trans-
plants [641. Given the incurability of the myeloma, patients would
have to have been in prolonged remission and have no other
contraindications to transplantation to make this option justifi-
able. I am not aware of any data suggesting that immunosuppres-
sion accelerates the course of rnyelorna.
DR. OR! S. BETFER (Department of Medicine, Technion, Israel
Institute of Technology, Haifa, Israel): Suppose you had seen the
patient you presented nine months prior to presentation when he
was still asymptomatic. What prophylactic measures would you
have prescribed to prevent acute renal failure?
DR. WINEARLS: I believe that chemotherapy given nine months
earlier when he was asymptomatic but had an ESR of >100
mm/hr would have prevented the development of renal failure. If
during followup his renal function had deteriorated, I would have
induced a diuresis, instituted plamsapheresis, and begun further
chemotherapy.
DR. BETrER: What would you do about a patient who has severe
bone pain and incipient myeloma kidney?
DR. WINEARLS: I would not use nonsteroidal anti-inflammatory
drugs but would rely on opiate analgesia and radiotherapy.
DR. JEAN-PIERRE GRUNFELD (Division of Nephrology, Hôpital
Necker): I note that your patient died of cardiac failure. It was not
related to amyloid deposition, and probably light-chain deposition
was not involved. Do you believe that adriamycin toxicity was
involved? Do you know whether the risk of cardiotoxicity is
increased in patients with renal failure?
DR. WINEARLS: Although this patient received less than 200
mg/rn2 of doxoruhicin, well below the cumulative dose of 450
mg/rn2 believed safe, I am suspicious that this was the cause of his
cardiomyopathy. The dose does not have to be reduced in renal
failure, for metabolism is predominantly via the liver.
DR. DAVISON: I am interested in your Oxford series of patients
and the distribution of patients by gender. You report a male:
female ratio of 2:1, which is the same as many glomerular
diseases, for example, rnembranous nephropathy. What is it about
male gender that renders males at higher risk for renal disease?
DR. WINEARLS: The ratio of males:females is about 1.5:1.0. This
might be a consequence of exposure to ionizing radiation and
certain industrial chemicals (reviewed in Ref. 2).
DR. V0sNIDEs: Do you recommend the use of calcitonin for the
control of pain?
DR. WINEARLS: I have no experience with using calcitonin to
control pain, and it is not specifically recommended by Alexanian
and Dimopoulos [30] or Newland [3].
Dr. Vosnides: I think the severity of acute myeloma kidney and
the rate of recovery depend on the quality of the primary care
service of each country. For example, in the United Kingdom,
where you have an extremely good primary care service through
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the general practitioners and the National Health Service, your
patients come to the hospital, that is, to the hematology or
nephrology department, much earlier than, for example, in my
country, where the primary care service is not so well developed.
Do you agree with that?
DR. WINEARLS: Primary care is good in the United Kingdom,
but diagnosis is still delayed. In approximately 35% of patients,
the interval between symptoms and diagnosis is three months,
and in 15% is six months [1]. The patients presenting to the
renal unit represent only 10% of myeloma patients, but they seem
to be those with the most advanced disease.
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